This is a past event. Registration is closed. View other Parenteral Drug Association - Asia Pacific office events.
Registration
Welcome and Workshop Introduction
Sungjei Park
  • Sungjei Park (Sr. Marketing Manager at bioMérieux Industrial Applications)

    Sungjei Park

    Sr. Marketing Manager at bioMérieux Industrial Applications
How to Get the Most Out of a CDMO Relationship
Jennifer Cheung•Michie (Mei Kuen) Ong

Effectively navigating a sponsor-CDMO partnership is a complex task with a mutually beneficial outcome. The chosen CDMO significantly impacts business success and maintaining a strong relationship hinges on recognizing each partner’s strengths and capabilities. This session will delve into potential partnership conflicts and the importance of working through short-term tensions to achieve long-term goals. Participants will apply the insights acquired from our presenters to navigate a sponsor-CDMO conflict, discovering effective ways to address the disagreement with respect, even in the face of unforeseen challenges.

  • Jennifer Cheung (VP Global QA Operations at Gilead Sciences)

    Jennifer Cheung

    VP Global QA Operations at Gilead Sciences
  • Michie (Mei Kuen) Ong (Executive Director, US Quality of WuXi Advanced Therapies)

    Michie (Mei Kuen) Ong

    Executive Director, US Quality of WuXi Advanced Therapies
Q&A
Jennifer Cheung•Michie (Mei Kuen) Ong
  • Jennifer Cheung (VP Global QA Operations at Gilead Sciences)

    Jennifer Cheung

    VP Global QA Operations at Gilead Sciences
  • Michie (Mei Kuen) Ong (Executive Director, US Quality of WuXi Advanced Therapies)

    Michie (Mei Kuen) Ong

    Executive Director, US Quality of WuXi Advanced Therapies
Coffee Break
Choosing the Right CDMO for Late-Phase Clinical Trials
Christy Eatmon
  • Christy Eatmon (Global SME, Sterile Drug Products at Thermo Fisher Scientific)

    Christy Eatmon

    Global SME, Sterile Drug Products at Thermo Fisher Scientific
Q&A
Christy Eatmon
  • Christy Eatmon (Global SME, Sterile Drug Products at Thermo Fisher Scientific)

    Christy Eatmon

    Global SME, Sterile Drug Products at Thermo Fisher Scientific
Product Demo by bioMerieux: Advanced Environmental Monitoring
HyongKwon Kwon

The traditional environmental monitoring is prone to human error. Lack of traceability also critical problem and it cause lots of manual step. The 3P ENTERPRISE bring digitalization and automation through three pilar of systems. The advanced environmental monitoring is not an option, it would be the essential in EM.

  • HyongKwon Kwon (Product Specialist at biomerieux Korea)

    HyongKwon Kwon

    Product Specialist at biomerieux Korea
Lunch Break
Positioning for Global Success: Navigating CDMO Landscape for New Modalities
Grace Lee, Ph.D, MBA, CQA

As the biopharmaceutical industry evolves with diverse new modalities and technical innovations, partnerships with Contract Development and Manufacturing Organizations (CDMOs) are becoming increasingly important. CDMOs must navigate a complex global landscape to remain competitive. This presentation focuses on the strategic decisions CDMOs face, particularly the comparative advantages of small versus large CDMOs. We will examine key considerations in selecting the right CDMO partner, with an emphasis on emerging modalities that require innovative approaches. Through case studies, the presentation offers actionable insights to help CDMOs to position themselves and to secure a competitive edge in the evolving industry.

  • Grace Lee, Ph.D, MBA, CQA (Founder, Principal Consultant of Elevalue Consulting LLC)

    Grace Lee, Ph.D, MBA, CQA

    Founder, Principal Consultant of Elevalue Consulting LLC
Q&A
Grace Lee, Ph.D, MBA, CQA
  • Grace Lee, Ph.D, MBA, CQA (Founder, Principal Consultant of Elevalue Consulting LLC)

    Grace Lee, Ph.D, MBA, CQA

    Founder, Principal Consultant of Elevalue Consulting LLC
How to Manage Tech Transfer & Quality Management Systems: A Johnson & Johnson Case Study
Meekyung Lim•Gail Ward
  • Meekyung Lim (Director, Partnership & External Supply Large Molecule of Johnson & Johnson)

    Meekyung Lim

    Director, Partnership & External Supply Large Molecule of Johnson & Johnson
  • Gail Ward (EVP/CQO at Samsung Biologics)

    Gail Ward

    EVP/CQO at Samsung Biologics
Q&A
Meekyung Lim•Gail Ward
  • Meekyung Lim (Director, Partnership & External Supply Large Molecule of Johnson & Johnson)

    Meekyung Lim

    Director, Partnership & External Supply Large Molecule of Johnson & Johnson
  • Gail Ward (EVP/CQO at Samsung Biologics)

    Gail Ward

    EVP/CQO at Samsung Biologics
Workshop
Jennifer Cheung•Grace Lee, Ph.D, MBA, CQA•Meekyung Lim•Michie (Mei Kuen) Ong•Gail Ward
  • Jennifer Cheung (VP Global QA Operations at Gilead Sciences)

    Jennifer Cheung

    VP Global QA Operations at Gilead Sciences
  • Grace Lee, Ph.D, MBA, CQA (Founder, Principal Consultant of Elevalue Consulting LLC)

    Grace Lee, Ph.D, MBA, CQA

    Founder, Principal Consultant of Elevalue Consulting LLC
  • Meekyung Lim (Director, Partnership & External Supply Large Molecule of Johnson & Johnson)

    Meekyung Lim

    Director, Partnership & External Supply Large Molecule of Johnson & Johnson
  • Michie (Mei Kuen) Ong (Executive Director, US Quality of WuXi Advanced Therapies)

    Michie (Mei Kuen) Ong

    Executive Director, US Quality of WuXi Advanced Therapies
  • Gail Ward (EVP/CQO at Samsung Biologics)

    Gail Ward

    EVP/CQO at Samsung Biologics

The information presented at this conference is accurate as of its launch date. However, the organizers retain the right to modify, update, or amend any details as needed. As we aim to provide the most current information and updates, we encourage you to check regularly for any changes.